LWY713 is a PROTAC-class FLT3 degrader (DC50=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models[1]. LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373), the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).
Molecular Weight:
838.95
Formula:
C43H54N10O8
Target:
Apoptosis,FLT3,PROTACs
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
